Company

Xequel Bio

Biotechnology Research Fort Worth, Texas, United States 6 employees

Employees: 6
Contacts: 1
Emails: 1

www.xequel.com LinkedIn

Xequel Bio Overview

Headquarters: Fort Worth, Texas, United States
Website: www.xequel.com
Industry: Biotechnology Research
Employees: 6
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Charleston

About Xequel Bio

Xequel Bio, Inc. is a clinical stage biopharmaceutical company advancing its proprietary aCT1 (alpha-Connexin carboxyl-Terminal 1 peptide) technology platform to develop drugs that will enable physicians to better manage a variety of indications involving inflammation and the body’s response to injury. aCT1 is a patented new chemical entity currently in development for multiple indications. The Company’s lead clinical programs include Granexin® gel in dermatology and iNexinTM ophthalmic solution in ophthalmology. The Company also has ongoing preclinical research in pulmonology.

Xequel Bio Contact Details

People in AeroLeads: 3
With contact data: 1
Email contacts: 1; 33.3% coverage

Xequel Bio Org Chart

Sample employees and titles

Name	Title	Location	Contact
Meghan Bowler	Associate Director of R&D, Pulmonology at Xequel Bio		View
Angela Dunn	Operation Lead at Xequel Bio	Summerville, South Carolina, United States	View
Christina Grek	Vice President, Research and Development, at Xequel Bio	Mount Pleasant, South Carolina, United States	Email